Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $338K fell 4.2% year over year, ahead of the -6.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at -16.8% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.2% holds above the trailing-twelve-month pace of -6.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.39M USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- -13.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.39M | -12.7% |
| FY2024 | 2024-12-31 | 1.59M | -26.7% |
| FY2023 | 2023-12-31 | 2.17M | -10.0% |
| FY2022 | 2022-12-31 | 2.41M | -4.0% |
| FY2021 | 2021-12-31 | 2.52M | — |
Depreciation & Amortization vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 depreciation & amortization of $1.38M is the 4th highest of the 10 companies compared; the peer median is $1.12M.
- Its year-over-year change of -6.3% is the 4th highest of 10, against a peer median of -11.7%.
- Over three fiscal years its annual growth of -16.8% compares with a peer median of -1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.92M | -17.6% | +20.3% | 9.3% | |
| LTM Mar 2026 | $3.18M | +0.0% | -1.1% | — | |
| LTM Mar 2026 | $2.47M | -8.6% | +70.7% | 55.3% | |
| LTM Mar 2026 | $1.38M | -6.3% | -16.8% | — | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $1.12M | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $914K | -11.7% | +0.4% | 9.2% | |
| LTM Mar 2026 | $723K | +20.9% | -1.3% | 4.9% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding FULC) | $1.12M | -11.7% | -1.1% | 7.1% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.